Pulmozyme: clinical and economic impacts
Perras C, Otten N
Record ID 31999008084
English, French
Authors' objectives:
To summarise the available evidence relating to the cost-effectiveness of pulmozyme in the treatment of cystic fibrosis (CF).
Authors' recommendations:
This study found that the most important factors affecting costs are the per diem rates and the number of hospitalisations. Considering the savings accrued from decreased hospitalisation, DNase is still a more costly alternative than no DNase.
Authors' methods:
Cost study
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/pubs/overpulmozyme-3.html
Year Published:
1996
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Costs and Cost Analysis
- Deoxyribonucleases
- Cystic Fibrosis
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.